Patients receiving treatment with St. John's wort or Phenytoin.
Strong inhibitors (eg, ketoconazole) or inducers (eg, rifampicin or St. John's Wort) of CYPA (within  weeks prior to the start of dosing in the study)
Patients must also avoid St. Johns Wort, an inducer of CYPA
Patients must be willing to not take St. John wort or grapefruit juice while participating in this trial and should avoid drugs that are strong inducers of P-gp, and to switch to alternative drugs when available
All herbal medicines (eg, St. John's wort), vitamins, and supplements consumed by the subject within the  days prior to receiving the first dose of AMG 
Use of St. Johns wort =<  days prior to registration
Concomitant use of strong cytochrome (CYP) inducers or inhibitors including nutraceutical preparations, e.g., grapefruit juice and St Johns wort
Patient must not be taking Rifampin or St John`s wort.
Subjects taking herbal supplements (St. John's Wort, gingko biloba, etc.) should discontinue these supplements  days prior to study registration.
Subjects being treated concurrently with any prohibited medications, including investigational medication, rifampin, St. John's wort, and potent CYPA inhibitors (excluding ketoconazole) unless continuation of such medications are determined by the investigator to be in the best interest of the patient
Use of St. Johns wort or rifampin
No concurrent herbal or unconventional therapy (e.g., St. John's wort)
Use of St. Johns Wort because of its effects on hepatic drug metabolism
Patient agrees to discontinue St. Johns Wort while receiving dasatinib therapy (discontinue St. Johns Wort at least  days before starting dasatinib)
Patient is not taking St. Johns Wort
Concomitant Rifampicin and St John's Wort (Warfarin may be used only with very close monitoring.)
All herbal medicines (e.g., St. Johns wort), vitamins, and supplements consumed by the subject within the  days prior to receiving the first dose of AMG , and continuing use, if applicable, will be reviewed by the principal investigator
Concomitant treatment with rifampin and St. Johns wort
Subjects taking medications that are known potent or moderate inducers/ inhibitors of CYPA (including St. John's Wort)
St. John's Wort may decrease everolimus exposure unpredictably and should be avoided.
All herbal medicines (e.g., St. Johns wort), vitamins, and supplements consumed by the subject within the  days prior to receiving the first dose of AMG , and continuing use, if applicable, will be reviewed by the principal investigator
Current or recent (=<  days prior to randomization) use of sorivudine, brivudine, and St. Johns wort
Patients taking herbal supplements (St. Johns Wort, gingko balboa, etc.) should discontinue these supplements two weeks prior to study registration
Potent inhibitors or inducers of CYPA within  weeks before the first dose of study treatment ( weeks for St John's Wort).
Concomitant treatment with rifampin or St. John's Wort; patients should discontinue these drugs at least  weeks prior to starting protocol treatment
Prohibited treatments and or therapies:\r\n* Category I drugs that are generally accepted to have a risk of causing Torsades de Pointes including: (patients must discontinue drug  days prior to starting dasatinib)\r\n** Quinidine, procainamide, disopyramide\r\n** Amiodarone, sotalol, ibutilide, dofetilide\r\n** Erythromycin, clarithromycin\r\n** Chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide\r\n** Cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine\r\n* Patient agrees to discontinue St. Johns wort while receiving dasatinib therapy (discontinue St. Johns wort at least  days before starting dasatinib)\r\n* Patient agrees that intravenous (IV) bisphosphonates will be withheld for the first  weeks of dasatinib therapy due to risk of hypocalcemia
All subjects must agree to stop the use of all herbal medicines (e.g., St. Johns wort), and supplements, within the  days prior to receiving the first dose of AMG , and during the protocol AMG  treatment (weeks -); subjects may renew the use of the above at week ; standard adult multi-vitamin is allowed
Concomitant Medications\r\n* Patient agrees to discontinue St. Johns Wort while receiving dasatinib therapy (discontinue St. Johns Wort at least  days before starting dasatinib)\r\n* Patient agrees that IV bisphosphonates will be withheld for the  weeks of dasatinib therapy
St. Johns Wort
Patients taking rifampin and/or St. John's Wort
No St John's wort supplement or other herbal supplementation is allowed while on trial; patients are not to take grapefruit juice during study treatment
Herbal remedies (e.g., St. John's wort) within  week of enrollment
Use of St. Johns Wort or rifampin (rifampicin) within the last  weeks
Use of St. Johns Wort or rifampin (rifampicin)
Concomitant use of St. Johns Wort or rifampin (rifampicin)
Concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or St John's Wort
Patients must be willing to discontinue taking dong quai and/or St. Johns wort
Has consumed herbs/fruits that may have an influence on pharmacokinetics (PK) of DS-b from  days ( days for St. John's wort) prior to the start of the study and throughout the entire study
